Skip to content
Close

Examining Trends
that Drive Decisions

2023 Drug Trend Report

The Navitus Difference:
Empowering clients and members

Publicly available data that shines a light on true drug cost and utilization is rare.

Navitus is proud to publish our 8th annual Drug Trend Report. This analysis provides insight to our commercial books of business trends for the period of 2022-2023 and discusses factors that influenced them.

snapshot-top call out-01-1

 

 

table_2023-Changes-in-Trend_v01

6.8%

Average Net Total Cost Trend for Commercial Clients from 2022 to 2023

$101.78

Net Cost, Net of Rebates
Per Member Per Month (PMPM) For Commercial Clients in 2023

Notable Trend Drivers

Average trend for commercial clients was influenced by both higher spend and utilization in the non-specialty category and increased utilization of lower cost medications within specialty.

snapshot significant trend driving categories-01-1

 

 

snapshot photo data drives decisions

 

Data Drives Decisions

The Drug Trend Report highlights our belief that our clients own their data. We believe they are entitled to the clarity that data access delivers, empowering them to make informed decisions about their benefit. True transparency such as this can transform the pharmacy benefits landscape and enable greater savings and affordability for people accessing prescription drug care.

We encourage you to explore the entirety of this report, including success stories like that of the Texas Association of Counties (TAC). As a Navitus client, their ability to make data-driven decisions has delivered them savings of $160 million.

For more in-depth analysis of 2023 trend and drug pipeline insights, download the Executive Summary.

Why Our Model Matters

Our company was built on the foundational principle of transparency and a commitment to a fully pass-through PBM model. This means:

  • Clients receive 100% of rebates and fees obtained. Our scale helps us buy well and access savings that reduce costs for clients.
  • Formulary decisions are clinically based and unincumbered by high cost/high rebate offerings. We drive to lowest net cost to manage overall cost.
  • Clients have unmatched data availability. They have full access to their data – at the individual claim level – to make the best decisions for their organization.

snapshot-29% commercial clients-1

1To Non-Specialty@2x-1

 

Methodology

The Navitus drug trend is calculated by comparing the net total cost per member per month (PMPM) for 2023 to that for 2022. Net cost PMPM represents full-year (Q1-Q4) data for total member copays and plan paid amounts minus manufacturer rebates and fees. This value is divided by the total number of members and by 12 months of the year.

Net total cost PMPM trend consists of two components: utilization and cost and includes both specialty and non-specialty drugs. Utilization trend measures the change in total days of therapy. Cost trend measures the change in net total drug cost per the above. This analysis included data for more than 500 clients, representing 3M members within Navitus’ commercial book of business, including plan sponsors and health plans. To be included, these organizations must have been clients of Navitus in both 2022 and 2023. Exclusions from this analysis include products administered at physicians’ offices, clinics and hospitals, COVID-19 vaccines and supplies, weight loss products and any additional savings from copay assistance programs.